Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P5SA
|
||||
Former ID |
DAP000375
|
||||
Drug Name |
Fluphenazine
|
||||
Synonyms |
Dapotum; Elinol; Flufenazin; Flufenazina; Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazinum; Ftorphenazine; Pacinol; Phthorphenazine; Prolixine; Sevinol; Siqualine; Siqualon; Triflumethazine; Vespazine; Yespazine; Flufenazina [DCIT]; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; SQ 4918; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Fluphenazine [INN:BAN]; Fluphenazinum [INN-Latin]; Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen (Tabl or elixir); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN); 1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-(9CI); 10-(3'-(4"-(beta-Hydroxyethyl)-1"-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] | Approved | [1], [2] | ||
Therapeutic Class |
Antipsychotic Agents
|
||||
Company |
Bristol-Myers Squibb
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H26F3N3OS
|
||||
InChI |
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
|
||||
InChIKey |
PLDUPXSUYLZYBN-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 69-23-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9223, 606306, 841998, 5329924, 7979286, 8152146, 10532904, 11111179, 11111180, 11212325, 11335686, 11360925, 11363183, 11364798, 11365745, 11367360, 11368307, 11369922, 11372419, 11372962, 11374514, 11375522, 11376469, 11378089, 11461897, 11466348, 11467468, 11485013, 11486275, 11489015, 11491235, 11492643, 11494103, 14832617, 24263032, 26751625, 29222507, 46506645, 47291093, 47291094, 47365145, 47588956, 47588957, 47662238, 47662239, 47736435, 47885368, 48110419, 48259193, 48259194
|
||||
SuperDrug ATC ID |
N05AB02
|
||||
SuperDrug CAS ID |
cas=000069238
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 1B receptor | Target Info | Modulator | [3] | |
KEGG Pathway | cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Serotonergic synapse | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT1 type receptor mediated signaling pathway | |||||
Reactome | Serotonin receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain. Psychopharmacology (Berl). 2008 Jan;195(4):559-68. Epub 2007 Sep 23. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 204). | ||||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.